Fig 1.
Schematic representation of citrullinated peptide in rheumatoid arthritis development.
Table 1.
Citrullinated peptide epitopes used in this study [2,1,27–3,1].
Fig 2.
Mean response to epitopes E1-E20 in RA samples, n = 70.
Each sample has been analyzed in duplicate, and in two independent ELISA experiments, with CV below 5% being considered as a reliable result.
Table 2.
Demographical and clinical features of RA patients and controls used in this study.
Fig 3.
Longitudinal study of patients across a set of antigens: RA (A), SLE (B) and healthy controls (C).
Fig 4.
Clinical (A) and analytical (B) sensitivity study of anti-E2 test vs controls.
HC = healthy control, JIA = juvenile idiopathic arthritis, SSc = systemic sclerosis, SLE = systemic lupus erythematosus, RA = rheumatoid arthritis. (B) Mean reactivity for 20 samples at onset is given.
Fig 5.
Correlation of anti-E1, anti-E2, ACPA and RF reactivity with number of inflamed joints in RA patients (n = 30; cohort data given in Table 2).